The U.S. Food and Drug Administration (FDA) has made their REMS requirements for transmucosal immediate-release fentanyl (TIRF) products more rigorous to minimize inappropriate prescriptions for the strong and highly addictive opioid. The REMS guidelines serve as a cost-benefit analysis tool for the FDA where healthcare professionals monitor patients’ tolerance to opioids and prescribe accordingly to avoid abuse.

Read more here.

More on: